title: Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa.
abstract: Little is known about the effect of human immunodeficiency virus type 1 (HIV-1) resistance mutations present at time of regimen switch on the response to second-line antiretroviral therapy in Africa. In adults who switched to boosted protease inhibitor-based regimens after first-line failure, HIV-RNA and genotypic resistance testing was performed at switch and after 12 months. Factors associated with treatment failure were assessed using logistic regression. Of 243 participants, 53% were predicted to receive partially active second-line regimens due to drug resistance. The risk of treatment failure was, however, not increased in these participants. In this African cohort, boosted protease inhibitors successfully resuppressed drug-resistant HIV after first-line failure.
authors.affiliation: Department of GlobalHealth, University of Amsterdam, Amsterdam, The Netherlands. k.sigaloff@pharmaccess.org
authors.forename: Kim C E
authors.initials: KC
authors.lastname: Sigaloff
authors.forename: Raph L
authors.initials: RL
authors.lastname: Hamers
authors.forename: Carole L
authors.initials: CL
authors.lastname: Wallis
authors.forename: Cissy
authors.initials: C
authors.lastname: Kityo
authors.forename: Margaret
authors.initials: M
authors.lastname: Siwale
authors.forename: Prudence
authors.initials: P
authors.lastname: Ive
authors.forename: Mariette E
authors.initials: ME
authors.lastname: Botes
authors.forename: Kishor
authors.initials: K
authors.lastname: Mandaliya
authors.forename: Maureen
authors.initials: M
authors.lastname: Wellington
authors.forename: Akin
authors.initials: A
authors.lastname: Osibogun
authors.forename: Wendy S
authors.initials: WS
authors.lastname: Stevens
authors.forename: Michèle
authors.initials: M
authors.lastname: van Vugt
authors.forename: Tobias F
authors.initials: TF
authors.lastname: Rinke de Wit
mesh_terms: D000328:Adult; D017954:Africa South of the Sahara; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D015331:Cohort Studies; D024882:Drug Resistance, Viral; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D008875:Middle Aged; D020125:Mutation, Missense; D011446:Prospective Studies; D012367:RNA, Viral / Q000097:blood / Q000235:genetics; D016879:Salvage Therapy / Q000379:methods*; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D012367:RNA, Viral